Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Brain & Development|July 19, 2005
Histone modifications in Rett syndrome lymphocytes: a preliminary evaluationWalter E Kaufmann, Mohammed H Jarrar, Judy S Wang, et al.
Cancer Immunology, Immunotherapy : CII|September 29, 2020
Phase I, first-in-human trial of programmed cell death receptor-1 (PD-1) inhibitor, JTX-4014, in adult patients with advanced, refractory, solid tumorsKyriakos P Papadopoulos, Nehal Lakhani, Gerald S Falchook, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 2, 2019
Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor ActivityDevalingam Mahalingam, Judy S Wang, Erika P Hamilton, et al.
Investigational New Drugs|August 20, 2025
Phase 1/2, open-label study of oral bacterial supplementation (EDP1503) plus pembrolizumab in participants with advanced or metastatic microsatellite-stable colorectal cancer, triple-negative breast cancer, and checkpoint inhibitor-relapsed tumorsJudy S Wang, Edward R Arrowsmith, J Thaddeus Beck, et al.
The American Journal of Gastroenterology|November 12, 2009
Elevated serum gastrin is associated with a history of advanced neoplasia in Barrett's esophagusJudy S Wang, Andrea Varro, Charles J Lightdale, et al.
Gynecologic Oncology|October 10, 2021
An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancerJoyce Liu, Howard Burris, Judy S Wang, et al.
Investigational New Drugs|April 11, 2023
Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumorsAnastasios Stathis, Anthony W Tolcher, Judy S Wang, et al.
Investigational New Drugs|April 19, 2023
A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumorsArvind Dasari, Erika P Hamilton, Gerald S Falchook, et al.
Targeted Oncology|November 19, 2024
Open-Label, Multicenter, Phase I Study to Assess Safety and Tolerability of Adavosertib Plus Durvalumab in Patients with Advanced Solid TumorsManish R Patel, Gerald S Falchook, Judy S Wang, et al.
Canadian Journal of Ophthalmology. Journal Canadien D'Ophtalmologie|March 17, 2021
Reversible HER2 antibody-drug conjugate-induced ocular toxicityAnushree Sharma, Kamran M Riaz, Mohsain S Gill, et al.
Pageof 3